European Pharmaceutical Review

FEBRUARY 2, 2024

The ATLab (Alpha Therapy Laboratory) Valenciennes in Onnaing, France, will produce lead-212 radioligand therapies. Facilitated by more than 3,000m² of floor space at the site, Orano Med shared that it is aiming to produce ten times this quantity by the end of the 2030. As a result, the project will receive public support of almost €3.8

Manufacturing 98

Manufacturing Distribution Leads Pharmaceutical 98

European Pharmaceutical Review

JUNE 10, 2024

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. This news follows the company beginning construction on a similar facility in France , which is set to produce lead-212 radioligand therapies for the European market.

Manufacturing 98

Manufacturing Distribution Pharmaceutical manufacturing Leads 98

European Pharmaceutical Review

NOVEMBER 2, 2022

According to IPPR’s research, the UK would need to invest an extra £62 billion in 2022 to overtake Israel, the leading R&D spender. percent of GDP by 2030, to level with R&D investment in Sweden, the US and Taiwan. An extra £8.5bn in R&D would need to be invested by the government by 2030. percent to 3.4

Government 98

Government Leads Manufacturing Medicine 98

European Pharmaceutical Review

OCTOBER 17, 2024

It will operate under Orano Med and focus on creating and trialling next-generation lead-212 ( 212 Pb) radioligand therapies. Sanofi will make an equity investment of €300 million, enabling Orano Med to accelerate the development of its pipeline, leveraging the company’s capabilities in lead-212 based therapy discovery and development.

Leads 52

Leads Biopharma Government Manufacturing 52

PharmExec

NOVEMBER 8, 2022

A shift in mindset to the experiment itself could lead the way.

Leads 52

Leads 52

Pharmaceutical Technology

JUNE 6, 2023

GlobalData’s Telehealth Market Size by Segments, Share, Trends, and Forecast, 2022-2030 report provides key insights into business strategies, trends driving the telehealth market and granular data on market segments forecast up to 2030. Buy the report here.

Media 40

Media Pharma Marketing Leads 40

European Pharmaceutical Review

AUGUST 22, 2024

Based on their rising popularity to treat type 2 diabetes and obesity, GlobalData has predicted that sales of glucagon-like peptide-1 receptor (GLP-1R) drugs will increase fourfold to an estimated $142 billion by 2030. 1 Considering the 11 approved GLP-1R drugs “generated $37.2 References GLP-1R Market: A Two Horse Race, Says Globaldata.

Medicine 59

Medicine Marketing Manufacturing Sales 59

Pharmaceutical Technology

MAY 29, 2023

GlobalData’s Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 report offers insights on application of blockchain in healthcare and other key sectors. For further understanding of GlobalData's Blockchain Market Size, Share, Trends, and Segment Forecast to 2030 buy the report here.

Pharmaceutical 52

Pharmaceutical Marketing Competition Medicine 52

European Pharmaceutical Review

JANUARY 22, 2024

million by 2030, according to a report by ResearchAndMarkets. Between 2023 to 2030, this represents a CAGR of 15.13 North America was leading the E&L testing services market with a revenue share of 43.71 The global extractable and leachable (E&L) testing services market is projected to value $2.57 percent in 2022.

Marketing 52

Marketing Safety Medicine Pharmaceutical 52

Pharmaceutical Technology

MAY 29, 2023

GlobalData’s Telehealth Market Size by Segments, Share, Trends, and Forecast, 2022-2030 report provides key insights into business strategies, trends driving the telehealth market and granular data on market segments forecast up to 2030. Buy the report here. Starting at 100 in 2020, an index over 100 is more positive.

Pharmaceutical 45

Pharmaceutical Marketing Leads 45

Pharmaceutical Technology

JUNE 30, 2022

By 2030, it strives to “free more than one billion people who currently require interventions against neglected tropical diseases.”. The post Neglected tropical diseases: non-profits lead the way as private sectors lags appeared first on Pharmaceutical Technology. Covid-19 strained development and treatment efforts. “The

Leads 64

Leads Pharma Medicine FDA 64

Pharmaceutical Technology

JUNE 7, 2023

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. There have been several Phase III trials for Mounjaro, with SURMOUNT-1 demonstrating a weight loss of up to 22.5%

Leads 98

Leads Marketing FDA Sales 98

European Pharmaceutical Review

AUGUST 16, 2024

He is “confident” in Rayne’s ability to “execute towards our 2030 vision to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO ® ) antibody medicines”.

Manufacturing 52

Manufacturing Distribution Management Government 52

European Pharmaceutical Review

NOVEMBER 9, 2022

Vinnova’s SEK320 million (€29 million) investment in Transfer, a two-year research project developing an AI-based quality control (QC) method using gene expression patterns to classify cells for Advanced Therapy Medicinal Product (ATMP) manufacturing , could lead to the method becoming the recommended ATMP QC method.

Manufacturing 98

Manufacturing Government Training Leads 98

Pharmaceutical Technology

APRIL 18, 2023

The drug constricts blood vessels leading to a reduction in swelling and inflammation of blood vessels associated with migraine. According to GlobalData , the global migraine market will be worth $18.6bn by 2030. Rizafilm’s active ingredient is rizatriptan – a serotonin (5-hydroxytryptamine or 5-HT) receptor agonist.

Food and Drug Administration 98

Food and Drug Administration FDA Food Marketing 98

European Pharmaceutical Review

MAY 2, 2024

As a result, the market is expected to reach $719 billion by 2030, 1 Sigma Mostafa, PhD, Chief Scientific Officer at KBI Biopharma shared with EPR. What excites me most is the continuous infusion of new modalities, unique conjugates, and enabling technologies leading to more targeted and effective therapies. Bn by 2030.

Medicine 105

Medicine Manufacturing Biopharma Engineering 105

World of DTC Marketing

JUNE 6, 2022

Diabetes can lead to serious health complications like heart disease and stroke, so it’s important to take steps to avoid developing the disease if possible. The study reveals that by 2030 the ratio will decline sharply to 4 to 1 and by 2050, 3 to 1. —and a silent killer. It doesn’t have to be this way. Care Giving Crisis.

Healthcare 174

Healthcare Healthcare Food Government 174

Pharmaceutical Technology

FEBRUARY 10, 2023

With the current market outlook, both 4DMT and Sangamo are the leading developers in the Fabry disease space, and GlobalData predicts that Sangamo’s therapy will likely achieve approval and a significant market share before 4DMT’s therapy as a result of the FDA clinical hold.

FDA 105

FDA Leads Competition Marketing 105

European Pharmaceutical Review

FEBRUARY 3, 2023

billion by 2030 The post France gets new sterile liquid drug manufacturing facility appeared first on European Pharmaceutical Review. The 9,500m 2 facility will harness state-of-the-art containment technologies, Baduel confirmed. The site will have approximately 100 employees and create 50 new jobs throughout 2023.

Manufacturing 98

Manufacturing Pharmaceutical Marketing Sales 98

European Pharmaceutical Review

SEPTEMBER 1, 2023

BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6 billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. subvariant.

Marketing 110

Marketing Sales Competition Pharmaceutical 110

European Pharmaceutical Review

JANUARY 27, 2023

This is an effort which aims to improve access and address barriers to quality healthcare for 30 million people living in limited-resource settings annually, by 2030.

Distribution 105

Distribution Transportation Medicine Medical 105

World of DTC Marketing

AUGUST 21, 2020

As the NY Times recently reported , obesity is the leading cause of mortality in the United States. An analysis is predicting that by 2030, 48.9% Obesity costs the nation $1.72 trillion every year. In the United States, where at least 4.6 of adults in the United States will be obese and 24.2% will be severely obese. .

Insurance 238

Insurance Physicians Healthcare Healthcare 238

World of DTC Marketing

AUGUST 22, 2022

Globally, nearly half of deaths due to cancer can be attributable to preventable risk factors, including three leading risks of smoking, drinking too much alcohol, or having a high body mass index, a new paper suggests. on cancer-related health care in 2015, and this amount is projected to grow to $246 billion by 2030—an increase of 34%.

Food 229

Food Education Government Patients 229

Pharmaceutical Technology

MAY 19, 2023

Multiple sclerosis (MS) is a primary autoimmune disease in which inflammation is a core contributor to the degeneration of the central nervous system (CNS), leading to neurological disability and affecting sensory, visual, motor, and autonomic systems. DMTs for MS have a high price tag, particularly in the US.

Prospecting 98

Prospecting Marketing Patients Leads 98

pharmaphorum

JANUARY 10, 2023

BioNTech’s chief executive Uğur Şahin said the acquisition will help “make BioNTech a technology company where AI is seamlessly integrated into all aspects of our work” as it stives to maintain its leading position in COVID-19 vaccines and continues to builds an oncology pipeline.

Manufacturing 115

Manufacturing Engineering Government Leads 115

Pharmaceutical Technology

MARCH 31, 2023

Kenya’s investments, trade, and industry cabinet secretary Moses Kuria said: “This investment creates the momentum to meet the $10bn annual target under the government’s manufacturing ’20 by 30′ vision, where we plan to grow the contribution of manufacturing to GDP to 20% by the year 2030 from the current 7%.”

Manufacturing 105

Manufacturing Government Medicine Healthcare 105

European Pharmaceutical Review

FEBRUARY 8, 2023

Yescarta for blood cancer Yescarta is targeting expansions into the first line for diffuse large B-cell lymphoma (DLBCL) and second line for follicular lymphoma in 2030. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7

Marketing 98

Marketing Sales Physicians Patients 98

pharmaphorum

JUNE 29, 2022

It is also being developed for use in pregnant women to prevent RSV in newborns, an indication for which it looks to be in the lead after GSK was forced to halt three clinical trials while it investigates a safety signal. For children younger than five years old in the US, the infection leads to approximately 2.1

Marketing 83

Marketing Leads Safety Sales 83

pharmaphorum

JANUARY 19, 2023

India’s Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of hair loss. The $11.50 The report predicts that the alopecia areata market will grow to as much as $2.5

Pharma 85

Pharma Marketing FDA Leads 85

World of DTC Marketing

AUGUST 19, 2022

1ne: A new analysis predicts that by 2030, 48.9% This is going to lead to a lot of health problems and associated costs. Congress has taken decisive action to reduce drug prices while ignoring that overall healthcare spending will be a substantial part of GNP. of adults in the United States will be obese, and 24.2% percent of U.S.

Healthcare 204

Healthcare Healthcare Insurance Competition 204

European Pharmaceutical Review

SEPTEMBER 7, 2023

It will also lead to greater regulatory alignment between the UK and EU, providing a huge boost to exporters, as well as improving the talent pool available to businesses and allowing for easier movement of researchers and professionals between the UK and the EU,” Brain explained.

Government 97

Government Competition Pharmaceutical Manufacturing 97

Clarivate

DECEMBER 6, 2023

By the year 2030, it is likely the legal space will look and operate differently to today, resulting in reshaping the way IP professionals at law firms and in-house councils work. from 2023 to 2030 and the AI market size is estimated to reach $407 billion by 2027. What could this mean for the future of the IP legal profession?

Management 59

Management Professional Services Recruitment Government 59

World of DTC Marketing

NOVEMBER 3, 2020

A prestigious team of medical scientists has projected that by 2030, nearly one in two adults will be obese, and nearly one in four will be severely obese. The Global Burden of Disease study estimates that high sodium intake causes between 1 million and 5 million deaths per year globally” Then there is the obesity epidemic.

Insurance 190

Insurance Healthcare Healthcare Physicians 190

Pharmaceutical Technology

MARCH 29, 2023

This next extension beyond 2030 is a testament to the success and trust of the partnership, as well as to the high degree of confidence placed in our platforms and the complementary approach to generating a leading pipeline of highly innovative drug candidates.

Food and Drug Administration 52

Food and Drug Administration Medicine Food FDA 52

pharmaphorum

JANUARY 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. If successful, the partnership may also lead to manufacturing investments in the UK.

Manufacturing 109

Manufacturing Patients Leads 109

European Pharmaceutical Review

AUGUST 19, 2022

Meanwhile, the presence of a significant number of pharmaceutical and biopharmaceutical companies, and several of the leading firms worldwide puts the US and Europe ahead in the global market. Lower labour costs, presence of significant talent pool and growing domestic markets are some of the factors driving growth in the Asia-Pacific region.

Manufacturing 98

Manufacturing Marketing Pharma Healthcare 98

Medico Reach

MARCH 24, 2023

It is further expected to reach USD 14,505 million in 2030. billion by 2030. It is expected to grow at a CAGR of 19.99% from 2022 to 2030. Proper research and investment in this field can lead to treating the disease efficiently. Nanotechnology By 2028, the Nanotechnology Medicines Delivery Market is expected to be $141.2

Marketing 52

Marketing Medicine Healthcare Healthcare 52